DarioHealth Corp. (DRIO) Is At $1.60 Formed Wedge; Aytu Bioscience (AYTU) SI Decreased By 14.81%

DarioHealth Corp. (DRIO) formed wedge down with $1.55 target or 3.00% below today’s $1.60 share price. DarioHealth Corp. (DRIO) has $22.14 million valuation. The stock increased 3.23% or $0.05 during the last trading session, reaching $1.6. About 115,914 shares traded or 22.04% up from the average. DarioHealth Corp. (NASDAQ:DRIO) has declined 46.73% since January 29, 2017 and is downtrending. It has underperformed by 63.43% the S&P500.

Aytu Bioscience Incorporated (NASDAQ:AYTU) had a decrease of 14.81% in short interest. AYTU’s SI was 18,400 shares in January as released by FINRA. Its down 14.81% from 21,600 shares previously. With 44,700 avg volume, 0 days are for Aytu Bioscience Incorporated (NASDAQ:AYTU)’s short sellers to cover AYTU’s short positions. The stock decreased 2.47% or $0.09 during the last trading session, reaching $3.56. About 62,359 shares traded. Aytu BioScience, Inc. (NASDAQ:AYTU) has 0.00% since January 29, 2017 and is . It has underperformed by 16.70% the S&P500.

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company has market cap of $17.44 million. The firm markets Natesto for the treatment of hypogonadism in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It currently has negative earnings. It is also involved in commercializing of the RedoxSYS System for research use in various applications.